Resident Doctors are on strike from 7 - 13 April. Please continue to attend appointments at the hospital unless you are contacted directly to rearrange. Our hospitals will be busy, but we are still here to provide emergency care when you need it.

Team Two Oncology Research Breast and Gynaecology

We aim to have a varied portfolio that allows patients to participate in various research and trials.

We mainly cover phase II-III research trials in breast and gynaecology. We are working on a phase 1b Gynaecology trial.

We are patient-centred and work collaboratively within the team, with patients and with clinicians. We are committed to excellence in health research, providing equal opportunities for treatments for all our patients.

Current studies

We have various recruiting studies covering everything from family history, surgery, adjuvant, radiotherapy, and metastatic disease. Below is a list of current recruiting studies:

·        Small. PI: Mr Brian Hogan: Open surgery versus minimally invasive vacuum-assisted excision of small screen-detected breast cancer – a phase III randomised multi-centre trial

·        POETIC-A : PI: Mr Baek Kim POETIC-A is a phase III, multi-centre, biomarker–stratified randomised trial. The trial has 2 parts; i) a screening-registration part where patients enriched for the subsequent eligible population receive AI treatment pre-surgery followed by ii) a randomised intervention part where patients whose early AI exposure is indicative of a sub-optimal endocrine response will receive standard endocrine therapy alone or abemaciclib with standard endocrine therapy.

·        ATNEC: PI: Miss Emma MacInnes A randomised trial investigating whether axillary treatment can be avoided in patients with no residual cancer in the lymph glands after chemotherapy.

·        Pre-Nutritive : PI: Sue Hartup To assess the feasibility of collecting nutritional metrics from TNBC patients during standard clinical care pathways and compare this to chemotherapy response

·        Ascent 3: PI: Prof Chris Twelves A Randomised, Open-label, Phase 3 Study of Sacituzumab Govitecan vs TPC in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic TNBC Whose Tumours Do Not Express PD-L1 or in Patients Previously Treated with Anti-PD-(L)1 Agents in the Early Setting Whose Tumours Do Express PD-L1

·        Ascent 4. PI: Prof Twelves: A Randomised, Open-label, Phase 3 Study of Sacituzumab Govitecan vs TPC in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic TNBC Whose Tumours Do Not Express PD-L1 or in Patients Previously Treated with Anti-PD-(L)1 Agents in the Early Setting Whose Tumours Do Express PD-L1

·        AL 2001: PI: Prof Twelves Phase II, open label, single arm study to investigate anti-tumor effect of ixabepilone in patients with locally recurrent or metastatic breast cancer (mBC) selected by the ixabepilone Drug Response prediction (DRP) after failure of an anthracycline and a taxane.(currently paused)

·        Cando-3 : PI: Sue Hartup Body composition and chemotherapy toxicity in women with early breast cancer

·        Destiny Respond  PI: Amy Burkinshaw A multi-center, multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+, and HER2-low unresectable and/or metastatic breast cancer

·        Real-World Patient-Reported outcomes: PI: Amy Burkinshaw Real-World Patient-Reported Outcomes in ER+/HER2- Advanced/Metastatic Breast Cancer

  • Pairs PI: Dr David Jackson Parp Inhibitor Resistance Study (PAIRS)
  • Monitor: PI: Dr David Jackson Multi-centre, observational study to follow patients with ovarian cancer on Niraparib maintenance in the UK
  • Valtive-1: PI: Dr Alison Young To define the Progression Free Survival (PFS) difference between Tie2-defined vascular responders and Tie2-defined vascular non-responders in patients receiving bevacizumab for high-risk Ovarian Cancer
  • Protector: PI Mr Richard Hutson – The study has three arms: risk reducing salpingo-oophorectomy (RRSO – current standard clinical practice), RRESDO (surgical alternative), control (no surgery). Women are given the option of self-selecting which of the three arms they wish to partake in
  • CRAIN: PI: Dr Rachel Cooper A phase 1b TiTE-CRM dose escalation clinical trial of tolinapant (ASTX660) in combination with standard radical chemoradiotherapy in cervical cancer

How to contact us

Email address
[email protected]
Phone number
0113 2068628
  • Page last reviewed: